Fred Hutch’s collaborative culture allows our researchers to generate discoveries as quickly as possible and translate them into new treatments, diagnostic tools and preventive strategies. Our integrated research centers, institutes, networks and other cross-divisional programs are crucial to maintaining that culture.
Fred Hutch is at the forefront of a fundamental shift in the way cancer is treated and cured. Our researchers are developing new ways to empower the immune system to fight cancer and other diseases, with potentially fewer side effects than with conventional treatments.
Each year, 14 million people worldwide are diagnosed with cancer, and up to 20 percent of those cancers are caused, directly or indirectly, by viruses and other pathogens. Fred Hutch’s goal is to lead the way in eliminating that burden by spurring advances in the understanding, prevention and treatment of pathogen-associated cancers.
We are building on recent data-driven advances in the biomedical sciences to open up new avenues for preventing and treating cancer and related diseases. Our data scientists develop statistical methods and computational tools for managing massive data sets and work closely with our researchers and clinicians to translate data-driven discoveries into improved patient care.
HICOR is a research institute at Fred Hutch whose mission is to improve cancer prevention, detection and treatment in ways that will reduce the economic and human burden of cancer — and ultimately lead to better outcomes for patients.
To achieve this, HICOR brings together researchers, patient partners, clinicians, payers and policymakers to share cancer-related data and generate clinically relevant performance metrics that can guide improvements in cancer care.
Based at Fred Hutch, the CITN and affiliated Immune Oncology Network (ION) strives to make promising experimental immunotherapies broadly available to people with cancer. The CITN benefits from the collective expertise of top academic immunologists to conduct multicenter research on novel immunotherapy agents that can unleash patient immunity to fight cancer. CITN’s early-phase trials are designed to provide critical data that can help speed potential therapies from the experimental stages to widespread use in treating patients.
Fred Hutch leads the HIV Vaccine Trials Network, a critical global effort aimed at creating an effective vaccine against HIV. HVTN operates over 30 sites on five continents and has collaborations with researchers at numerous internationally renowned research institutes.
STTR connects scientists across disciplines and institutions — including Fred Hutch, UW Medicine, and Seattle Children’s — to enable discoveries that lead to new methods for cancer prevention, early diagnosis and treatment. STTR offers advanced tools, resource development and administrative support.
The IHWG provides a comprehensive inventory of human leukocyte antigen (HLA) reference genes to support worldwide research in immunogenetics. It also offers selected cell lines and DNA from its substantial bank, which includes more than 1,000 cell lines from selected families and individuals with varied ethnic and immunologic backgrounds.
The SAN is a network of Pacific Northwest research institutions focused on supporting and accelerating innovations in patient care. Together, we are working to facilitate access to specimens for our research communities for the development of new methods of preventions, diagnostics and treatments.
Fred Hutch has a growing cross-divisional Global Oncology program that investigates globally relevant cancers and seeks to understand the varied genetics and biology of common cancers around the world. Through our Global Oncology program, we aim to develop high-impact, low-cost diagnostic tools and therapies that can be used in low-resource settings worldwide.
The Fred Hutch Innovation Lab is spurring novel technology development and adoption. Scientists are leading the in-house development and early adoption of powerful new research technologies that hold the potential to drive lifesaving discoveries in cancer immunology and other areas of science.
The Office of Community Outreach and Engagement promotes health equity by generating and facilitating cancer research that addresses and reduces cancer health disparities in the catchment area through authentic engagement, a community-engaged/community-based participatory research approach and education driven by community need.
The Population Health Colorectal Cancer Screening Program is a collaborative effort between Fred Hutch and UW Medicine. The program's goals are to eradicate colorectal cancer by improving screening, reducing racial, ethnic, and socioeconomic disparities, and improving follow-up for those with abnormal non-invasive screening tests.
The Center for Metastasis Research eXcellence (MET-X) is an interdisciplinary and collaborative program at Fred Hutch focused on one of the most challenging areas of cancer biology: metastasis, or the spread, colonization and deadly growth of tumor cells in distant sites. Metasasis is the underlying cause of most solid tumor cancer deaths.
Our world-class scientists have revolutionized prevention, detection and treatment of many cancers and other diseases.
Researchers in our five scientific divisions are generating pathbreaking discoveries and translating them into interventions that save lives.